On February 28, 2021, the U.S. Food and Drug Administration authorized the Johnson & Johnson COVID-19 vaccine for emergency use, the third such vaccine approved in the United States. The single-dose vaccine expanded access and accelerated the national vaccination campaign amid the pandemic. It played a critical role in reducing hospitalizations and improving public health response efficiency.
